Clinical Study for IOPD Participants Less Than or Equal to 6 Months of age to Evaluate Efficacy and Safety of enzyme replacement therapy (ERT) WithAvalglucosidase Alfa(Baby-COMET) Clinical Study for IOPD Participants Less Than or Equal to 6 Months of age to Evaluate Efficacy and ...
An Open-label, Multinational, Multicenter, Intravenous Infusion Study of the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of avalglucosidase alfa inTreatment-naïve Pediatric Participants Less than or Equal to 6 Months of Age with Infantile-Onset Pompe Disease (IOPD) - Baby-COMET An Open-label, Multinational, Multicenter, Intravenous Infusion Study of the Efficacy, Safety, Pharm ...
Glycogen storage disease type II MedDRA version: 20.1;Level: PT;Classification code 10053185;Term: Glycogen storage disease type II;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] Glycogen storage disease type II MedDRA version: 20.1;Level: PT;Classification code 10053185;Term: G ...
Product Name: Avalglucosidase Alfa Product Code: [GZ402666] INN or Proposed INN: avalglucosidasi alfa Other descriptive name: RECOMBINANTHUMANALFA-GLUCOSIDASECONJUGATEDWITHSYNTHETICBISMANNOSE-6-PHOSPHATE-MAN6GLYCANProduct Name: Avalglucosidase Alfa Product Code: [GZ402666] INN or Proposed INN: avalglucosidasi alfa O ...